Larotrectinib
- Generic Name
- Larotrectinib
- Brand Names
- Vitrakvi
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22F2N6O2
- CAS Number
- 1223403-58-4
- Unique Ingredient Identifier
- PF9462I9HX
- Background
Larotrectinib is an orally administered tropomyosin receptor kinase (Trk) inhibitor with demonstrated antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpre...
- Indication
用于治疗携带NTRK基因融合的局部晚期或转移性实体瘤的成人和儿童患者。包括肺癌、甲状腺癌、黑色素瘤、胃肠癌、结肠癌、软酿肉瘤、唾液腺、婴儿纤维肉瘤、阑尾癌、乳腺癌、胆管癌、胰腺癌等多种疾病。
- Associated Conditions
- NTRK1 Fusion Positive, NTRK2 Fusion Positive, NTRK3 Fusion Positive
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath